Belle Mead, NJ, United States of America

William H Parsons

This inventor holds 64 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Compounds (CPC class 5143). Top assignees: Merck + Co., Inc., Janssen Pharmaceutica Nv, Evotec Oai. Active years: 1987-2011.

USPTO Granted Patents = 64 (Patent Applications = 3)

% Patents Active = 92.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 17

Forward Citations = 922(Granted Patents)

Forward Citations (Not Self Cited) = 886(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Avenel, NJ (US) (1989)
Birmingham, AL (US) (1993)
Rahway, NJ (US) (1987 - 1994)
Baton Rouge, LA (US) (1995)
Edison, NJ (US) (1993 - 2002)
Belle Mead, NJ (US) (1997 - 2011)

Company Filing History:

Janssen Pharmaceutica Nv

4. 3 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2011

Loading Chart...

Areas of Expertise:

Sodium Channel Blockers

Chemokine Receptor Modulators

Immunosuppressant Compounds

Triterpene Derivatives

Potassium Channel Inhibitors

SRC Kinase Inhibitors

Benzimidazole Inhibitors

Ocular Hypertension Treatments

Biaryl Substituted Compounds

Macrolides

Cholesterol Lowering Agents

Pyrrolidine Modulators

64 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7951829 - Benzimidazole modulators of VR1 (2011-05-31),

2. 7612211 - Benzimidazole TRPV1 inhibitors (2009-11-03),

3. 7589116 - Biaryl substituted pyrazoles as sodium channel blockers (2009-09-15),

4. 7572822 - Biaryl substituted triazoles as sodium channel blockers (2009-08-11),

5. 7459475 - Substituted triazoles as sodium channel blockers (2008-12-02),

6. 7414067 - Ophthalmic compositions for treating ocular hypertension (2008-08-19),

7. 7348348 - Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers (2008-03-25),

8. 7326726 - Biaryl substituted triazoles as sodium channel blockers (2008-02-05),

9. 6632836 - Carbocyclic potassium channel inhibitors (2003-10-14),

10. 6545023 - Cyclopentyl modulators of chemokine receptor activity (2003-04-08),

11. 6498165 - Src kinase inhibitor compounds (2002-12-24),

12. 6489354 - 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity (2002-12-03),

13. 6455548 - 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity (2002-09-24),

14. 6372764 - Pyrrolidine modulators of chemokine receptor activity (2002-04-16),

15. 6362201 - 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity (2002-03-26),

Title: **The Innovations of William H. Parsons**

Introduction

William H. Parsons, based in Belle Mead, NJ, is a prolific inventor known for his significant contributions to the field of pharmaceuticals. With a remarkable total of 64 patents to his name, Parsons has focused on the development of innovative compounds aimed at addressing various medical conditions.

Latest Patents

Among his latest patents, Parsons has developed:

1. **Benzimidazole Modulators of VR1** - This invention is directed towards compounds of Formula (I) and involves pharmaceutical compositions containing such compounds along with methods of treatment utilizing them.

2. **Benzimidazole TRPV1 Inhibitors** - Similar to his previous work, this invention also focuses on compounds of Formula (I) and includes pharmaceutical compositions and the methods of treatment that employ these new compounds.

Career Highlights

Throughout his career, William H. Parsons has worked with notable companies, including Merck & Company, Inc. His expertise in drug development and innovation has greatly influenced pharmaceutical advancements.

Collaborations

Parsons has collaborated with talented individuals in his field, including Kathleen M. Rupprecht and Robert K. Baker. These partnerships have contributed to his successful patent developments and innovative research efforts.

Conclusion

William H. Parsons continues to be a key figure in pharmaceutical innovation, with his significant patent portfolio illustrating his dedication to advancing medical science. His work not only showcases his inventive spirit but also reflects the collaborative nature of research and development in the industry.